RxDoctor Payments Data

Anne Wissman, APRN

Family · Brandon, FLNPI 1437757184

Payments from drug & device makers

$8,170in general payments, 2019–2025

Across 361 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Boston Scientific$974
  • AbbVie$920
  • Medtronic$663
  • Curonix LLC$597
  • Scilex Pharmaceuticals Inc.$446
  • plus $4K from 43 others

What the payments were for

  • Travel & lodging$6678%
  • Food & beverage$7,49592%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,170 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$79,824
Medicare patients
126
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant51$57,763
UbrelvyUbrogepant40$51,713
RelistorMethylnaltrexone Bromide19$44,320
ZtlidoLidocaine30$26,027
LinzessLinaclotide37$20,028
MovantikNaloxegol Oxalate35$15,221
Lidocaine97$11,519
Naloxone Hcl144$7,683
Cyclobenzaprine Hcl392$6,095
Pregabalin182$5,484
Gabapentin338$4,674
Tizanidine Hcl257$4,615
Diclofenac Sodium59$1,080
Methocarbamol57$768
Ondansetron OdtOndansetron23$737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Linzess$920$129,504128 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,009$44,32019 claims
Scilex Pharmaceuticals Inc.Ztlido$446$26,02730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →